Multiple myeloma (C90.0) is a malignant hematologic neoplasm characterized by the clonal proliferation of plasma cells in the bone marrow. These malignant plasma cells produce excessive amounts of a single monoclonal immunoglobulin (M-protein) or light chains, which can be detected in serum or urine. This condition typically disrupts normal hematopoiesis and leads to systemic complications often summarized by the 'CRAB' acronym: hypercalcemia, renal insufficiency, anemia, and lytic bone lesions. It frequently evolves from precursor states such as monoclonal gammopathy of undetermined significance (MGUS) and smoldering multiple myeloma (SMM). Diagnostic criteria require a biopsy showing 10% or more clonal bone marrow plasma cells or a biopsy-proven plasmacytoma, plus one or more myeloma-defining events (MDEs).
Distinguish clearly between multiple myeloma not having achieved remission, in remission, and in relapse to ensure fifth-character specificity.
Example: Patient with IgG kappa multiple myeloma, currently in relapse after 18 months of maintenance therapy with lenalidomide. Evidence of new lytic lesions on skeletal survey and rising M-protein levels. C90.02 (Multiple myeloma in relapse) is assigned. The patient's risk profile (HCC 10) is significantly higher due to the relapse status compared to stable remission.
Billing Focus: Remission status (0 for not having achieved remission, 1 for in remission, 2 for in relapse).
Document associated CRAB criteria including hypercalcemia, renal insufficiency, anemia, and bone lesions as these are primary indicators of symptomatic disease.
Example: Multiple myeloma with acute kidney injury due to cast nephropathy. Serum calcium is 11.2 mg/dL. Hemoglobin 9.4 g/dL. Documentation supports C90.00 along with N17.9 (Acute kidney failure) and E83.52 (Hypercalcemia). This captures the full complexity of the clinical encounter for billing and risk adjustment.
Billing Focus: Comorbid conditions like renal failure and hypercalcemia must be documented as secondary codes to support high-level E/M coding.
Specify the monoclonal protein type (e.g., IgG, IgA, Light Chain) and light chain isotype (kappa or lambda) within the narrative note.
Example: Diagnosis: IgA lambda multiple myeloma, not having achieved remission. Patient presents for cycle 2 of VRd protocol. Bone marrow biopsy confirms 40 percent plasma cell infiltration. Coding: C90.00. Billing requires specific capture of the neoplastic process and the complexity of the systemic treatment plan.
Billing Focus: Laterality is not applicable, but specific cytogenetic markers should be noted to justify medical necessity for high-cost biologic therapies.
Document the presence and site of any pathological fractures resulting from myeloma-induced osteolytic activity.
Example: Multiple myeloma in relapse (C90.02) complicated by a pathological fracture of the T12 vertebra (M84.58XA). Documenting the fracture site and encounter type (initial, subsequent, or sequela) is essential for orthopedic and oncologic billing.
Billing Focus: Use of additional codes for pathological fracture (M84.5 series) and sequencing the neoplasm code first.
Explicitly state the relationship between the myeloma and any extramedullary involvement if present.
Example: Multiple myeloma, not in remission (C90.00), with extramedullary plasmacytoma involving the thoracic soft tissue (C90.20). Documentation reflects systemic and localized plasma cell proliferation, affecting both billing for systemic therapy and localized radiation therapy.
Billing Focus: Differentiate between solitary plasmacytoma and multiple myeloma with extramedullary spread.
Typically used for routine follow-up of myeloma patients with stable disease but requiring monitoring of drug toxicities.
Required for myeloma patients in relapse, those experiencing severe treatment toxicity, or those with significant comorbidities like acute renal failure.
Gold standard for diagnosing multiple myeloma and assessing remission/relapse status.
Essential for measuring the M-spike, which correlates with tumor burden.
Used to detect Bence-Jones proteins and monitor renal involvement.
Standard of care for administering many myeloma treatments like daratumumab.
Used to assess the extent of bone marrow involvement and identify lytic lesions not seen on X-ray.
Commonly used medication in induction and relapse regimens.
Crucial for monitoring 'light chain only' myeloma and determining the light chain ratio.
Part of a comprehensive skeletal survey to identify bone destruction.